Medtronic Signs Exclusive Deal for Kuros’ MagnetOs Bone Graft in U.S. Spine Market

Medtronic will serve as the exclusive sales agent for Kuros Biosciences' MagnetOs bone graft technology in select U.S. spine markets under a five-year agreement announced by Kuros. MagnetOs, a ceramic bone graft substitute, offers a minimally invasive alternative to traditional autografts, demonstrating superior spinal fusion rates in clinical trials. This collaboration builds on an earlier trial agreement and aims to leverage Medtronic's extensive sales force to scale up Kuros’ revenue growth and operational efficiency. Medtronic will focus on spine-related applications while Kuros retains sales rights for other regions and medical indications.

The deal comes amid growing demand for advanced bone graft substitutes, with MagnetOs achieving a 149% sales increase in 2024. MagnetOs has shown a fusion rate of 79% in clinical trials compared to 47% for autografts, significantly outperforming similar ceramic devices like Nuvasive's Attrax. As Medtronic expands its spinal product portfolio, the partnership positions both companies to capitalize on the rising adoption of biocompatible, cost-effective bone graft technologies in the $1 billion extremities market.